Rheumatoid arthritis (RA) may not just be associated with, it may also directly cause, idiopathic pulmonary fibrosis (IPF), suggest findings from a new study. Published in Med Research, the work also identifies 2 shared biomarkers that may help predict which RA patients are most at risk of developing the deadly lung disease.
According to the researchers, their study is the first to demonstrate a causal role for RA in the development of IPF, supported by genetic evidence and molecular profiling. For rheumatologists and pulmonologists, explain the group, the findings underscore the importance of cross-specialty collaboration.
RA is best known for damaging joints but is also capable of triggering complications beyond them, including pulmonary fibrosis, where progressive scarring of the lungs leads to respiratory failure. Up to 40% of RA patients show evidence of interstitial lung disease (ILD), and IPF is among the most severe outcomes. It’s been estimated that patients with RA-ILD have a 3-fold increase in mortality compared with patients with RA alone.2
“Observational studies suggest an association, yet causality remains unclear due to confounding and reverse causation,” noted the researchers, adding that distinguishing correlation from causation has been difficult due to overlapping risk factors and confounding variables.1
To help mitigate this barrier, the group applied a genetic approach to their study. The team performed a bidirectional Mendelian randomization (MR) analysis, using genome-wide association study (GWAS) data from over 57,000 patients, with 14,000 RA and 43,000 controls, as well as 1028 patients with IPF and nearly 197,000 controls.
The discovery carries several important implications for clinicians, explained the researchers. | Image credit: vladimircaribb – stock.adobe.com.
They found that RA was found to increase the risk of IPF by approximately 16% (OR, 1.156; 95% CI, 1.054-1.267; P = .002). Sensitivity analyses confirmed that the result was not due to genetic overlap or hidden confounders. Notably, the reverse was not true, meaning IPF did not appear to cause RA.
“The lack of reverse causality suggests IPF is a consequence, not a precursor, of RA,” described the researchers.
To probe biological mechanisms, the team integrated transcriptomic datasets, plasma samples, and single-cell RNA sequencing from RA patients. They identified 2 chemokines—CCL2 and CXCL2—as potential shared biomarkers of RA and IPF. Identifying these shared biomarkers, wrote the researchers, opens new avenues for early diagnosis and targeted therapy in patients with RA at risk for lung complications.
Both markers were elevated in RA plasma compared with healthy controls. CCL2 was particularly enriched in fibroblasts, pericytes, and endothelial cells, while CXCL2 was highly expressed in myeloid cells. These chemokines interact with the ACKR1 receptor on endothelial cells, a pathway that may promote immune cell infiltration and fibrosis in the lungs.
Diagnostic testing reinforced this finding, with ROC curve analysis showing that CXCL2, alone or combined with CCL2, had strong predictive accuracy (AUC 0.875 and 0.867, respectively) for distinguishing RA patients with fibrotic risk.
The discovery carries several important implications for clinicians, explained the researchers. First, patients with RA who have persistently elevated CCL2 or CXCL2 could be flagged for closer monitoring of lung function. Second, targeting these pathways therapeutically, by modulating chemokine signaling, may represent a strategy to slow or prevent fibrosis.
The study was limited by several factors, including reliance on GWAS datasets of predominantly European ancestry and a relatively small validation cohort of 40 patients with RA. Larger, multi-ethnic studies will be needed to confirm the generalizability of results. Moreover, functional studies are required to directly test how CCL2 and CXCL2 drive fibrosis.
References
1. Pan X, Jiang C, Chen J, Sun T, Wang X, Chen J. Causal link and shared biomarkers between rheumatoid arthritis and idiopathic pulmonary fibrosis. Med Res. Published online July 25, 2025. doi:10.1002/mdr2.70021
2. Rojas-Serrano J. Progressive pulmonary fibrosis in rheumatoid arthritis–associated interstitial lung disease. J Rheumatol. 2025;52(8). doi:10.3899/jrheum.2024-1333